Active Ingredient(s): Triheptanoin
FDA Approved: * June 30, 2020
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Dojolvi Overview

Triheptanoin, sold under the brand name Dojolvi, is a medication for the treatment of children and adults with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).[1][2][3] The most common adverse reactions include abdominal pain, diarrhea, vomiting, and nausea.[1][2][3] Triheptanoin was approved for medical use in the United States in June 2020.[4][2&a...

Read more Dojolvi Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Dojolvi Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Liquid: 100% W/w, 35%
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Dojolvi: (1 result)

Sorted by National Drug Code
  • 69794-050 Dojolvi .96 g/ml Oral Liquid by Ultragenyx Pharmaceutical Inc.

Other drugs which contain Triheptanoin or a similar ingredient: (1 result)